

Meglumine antimoniate



Essential medicine status ✓

Section: [6. Anti-infective medicines](#) > [6.5. Antiprotozoal medicines](#) > [6.5.2. Antileishmaniasis medicines](#)

		EMLc	ATC codes: P01CB01
Indication	Mucocutaneous leishmaniasis	ICD11 code: 1F54.2	
Medicine type	Chemical agent		
List type	Core		
Formulations	Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule		
EML status history	First added in 1987 (TRS 770) Changed in 1989 (TRS 796) Changed in 2002 (TRS 914) Changed in 2007 (TRS 950) Changed in 2009 (TRS 958) Changed in 2023 (TRS 1049)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more about patents .		
Wikipedia	Meglumine antimoniate		
DrugBank	Meglumine antimoniate (Pentavalent Antimony)		

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for sodium stibogluconate / meglumine antimoniate on the EML and EMLc be amended to list each medicine separately with updated dosage form descriptions as follows: Sodium stibogluconate: Injection: 100 mg/mL in 30 mL vial Meglumine antimoniate: Injection: 1.5 g/5 mL in 5 mL ampoule

